Sanofi SA (ADR) (NYSE:SNY) reported that first quarter 2014 net sales decreased 2.7% on a reported basis, but grew 3.5% at CER. Business net income likewise grew 5.6% at CER and the business EPS grew by 5.8% at CER. The $0.80 EPS was lower than the analysts’ consensus estimate, but the company more than made up for it with the guidance for 2014 business EPS, which they pegged to be in the range of 4% and 7% at CER. Sanofi SA (ADR) (NYSE:SNY) net profit margin is 9.30% and weekly performance is 0.38%. On last trading day company shares ended up $53.00. Analysts mean target price for the company is $57.88. Sanofi SA (ADR) (NYSE:SNY) distance from 50-day simple moving average (SMA50) is 4.72%.
Auxilium Pharmaceuticals, Inc. (NASDAQ:AUXL), a fully integrated specialty biopharmaceutical company, announced that new analyses of data were presented from its clinical program and pivotal IMPRESS (The Investigation for Maximal Peyronie’s Reduction Efficacy and Safety Studies) trials, the Phase 3 studies that evaluated XIAFLEX(R) (collagenase clostridium histolyticum or CCH) for the treatment of Peyronie’s disease (PD). These data were presented at the American Urological Association (AUA) Meeting held in Orlando, Florida on May 16-21, 2014. Auxilium Pharmaceuticals, Inc. (NASDAQ:AUXL) shares advanced 1.64% in last trading session and ended the day on $19.79. AUXL gross Margin is 72.80% and its return on assets is -6.40%.Auxilium Pharmaceuticals, Inc. (NASDAQ:AUXL) quarterly performance is -30.07%.
VIVUS, Inc. (NASDAQ:VVUS) on May 15 announced that a poster describing results of an analysis of the association between weight loss with Qsymia® (phentermine and topiramate extended-release) capsules CIV and annual concomitant medication costs will be presented at the AACE 23rd Annual Scientific & Clinical Congress at the Paris Las Vegas Hotel, Las Vegas, NV. VIVUS, Inc. (NASDAQ:VVUS) shares moved down -2.69% in last trading session and was closed at $4.70, while trading in range of $4.63 – $4.89. VIVUS, Inc. (NASDAQ:VVUS) year to date (YTD) performance is -48.24%.
Orexigen Therapeutics, Inc. (NASDAQ:OREX) Revenues for each of the three months ended March 31, 2014 and 2013 were $857,000 and represent revenue recognized under our collaboration agreement with Takeda. Orexigen Therapeutics, Inc. (NASDAQ:OREX) ended the last trading day at $5.50. Company weekly volatility is calculated as 5.33% and price to cash ratio as 4.12.Orexigen Therapeutics, Inc. (NASDAQ:OREX) showed a positive weekly performance of 1.10%.
Wipro Ltd. a leading global Information Technology, Consulting and Outsourcing company announced a strategic partnership with Takeda Pharmaceutical Company Ltd. (ADR) (OTCMKTS:TKPYY) the largest pharmaceutical company in Japan and one of the global leaders of the industry. On last trading day company shares ended up $22.19.